1
|
Gewirtz-Meydan A, Koós M, Nagy L, Kraus SW, Demetrovics Z, Potenza MN, Ballester-Arnal R, Batthyány D, Bergeron S, Billieux J, Burkauskas J, Cárdenas-López G, Carvalho J, Castro-Calvo J, Chen L, Ciocca G, Corazza O, Csako R, Fernandez DP, Fujiwara H, Fernandez EF, Fuss J, Gabrhelík R, Gjoneska B, Gola M, Grubbs JB, Hashim HT, Islam MS, Ismail M, Jiménez-Martínez MC, Jurin T, Kalina O, Klein V, Költő A, Lee SK, Lewczuk K, Lin CY, Lochner C, López-Alvarado S, Lukavská K, Mayta-Tristán P, Miller DJ, Orosová O, Orosz G, Ponce FP, Quintana GR, Quintero Garzola GC, Ramos-Diaz J, Rigaud K, Rousseau A, De Tubino Scanavino M, Schulmeyer MK, Sharan P, Shibata M, Shoib S, Sigre-Leirós V, Sniewski L, Spasovski O, Steibliene V, Stein DJ, Strong C, Ünsal BC, Vaillancourt-Morel MP, Van Hout MC, Bőthe B. Global cross-cultural validation of a brief measure for identifying potential suicide risk in 42 countries. Public Health 2024; 229:13-23. [PMID: 38382177 DOI: 10.1016/j.puhe.2023.12.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 12/11/2023] [Accepted: 12/29/2023] [Indexed: 02/23/2024]
Abstract
OBJECTIVES This study aimed to examine the psychometric properties of the P4 suicide screener in a multinational sample. The primary goal was to evaluate the reliability and validity of the scale and investigate its convergent validity by analyzing its correlation with depression, anxiety, and substance use. STUDY DESIGN The study design is a cross-sectional self-report study conducted across 42 countries. METHODS A cross-sectional, self-report study was conducted in 42 countries, with a total of 82,243 participants included in the final data set. RESULTS The study provides an overview of suicide ideation rates across 42 countries and confirms the structural validity of the P4 screener. The findings indicated that sexual and gender minority individuals exhibited higher rates of suicidal ideation. The P4 screener showed adequate reliability, convergence, and discriminant validity, and a cutoff score of 1 is recommended to identify individuals at risk of suicidal behavior. CONCLUSIONS The study supports the reliability and validity of the P4 suicide screener across 42 diverse countries, highlighting the importance of using a cross-cultural suicide risk assessment to standardize the identification of high-risk individuals and tailoring culturally sensitive suicide prevention strategies.
Collapse
Affiliation(s)
- A Gewirtz-Meydan
- School of Social Work, Faculty of Social Welfare and Health Sciences, University of Haifa, Israel. Agewirtz-@univ.haifa.ac.il
| | - M Koós
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Forensic Psychiatry and Sex Research, University of Duisburg-Essen, Essen, Germany
| | - L Nagy
- Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
| | - S W Kraus
- Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV, USA
| | - Z Demetrovics
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Centre of Excellence in Responsible Gaming, University of Gibraltar, Gibraltar, Gibraltar
| | - M N Potenza
- Yale University School of Medicine, New Haven, CT, USA; Connecticut Council on Problem Gambling, Wethersfield, CT, USA
| | - R Ballester-Arnal
- Departmento de Psicología Básica, Clínica y Psicobiología, University Jaume I of Castellón, Spain
| | - D Batthyány
- Institute for Behavioural Addictions, Sigmund Freud University Vienna, Austria
| | - S Bergeron
- Département de Psychologie, Université de Montréal, Montréal, Canada
| | - J Billieux
- Institute of Psychology, University of Lausanne, Lausanne, Switzerland; Center for Excessive Gambling, Addiction Medicine, Lausanne University Hospitals (CHUV), Lausanne, Switzerland
| | - J Burkauskas
- Laboratory of Behavioral Medicine, Neuroscience Institute, Lithuanian University of Health Sciences, Lithuania
| | - G Cárdenas-López
- Virtual Teaching and Cyberpsychology Laboratory, School of Psychology, National Autonomous University of Mexico, Mexico
| | - J Carvalho
- William James Center for Research, Departamento de Educação e Psicologia, Universidade de Aveiro, Aveiro, Portugal
| | - J Castro-Calvo
- Department of Personality, Assessment, and Psychological Treatments, University of Valencia, Spain
| | - L Chen
- Department of Psychology, College of Humanity and Social Science, Fuzhou University, China
| | - G Ciocca
- Section of Sexual Psychopathology, Department of Dynamic and Clinical Psychology, and Health Studies, Sapienza University of Rome, Rome, Italy
| | - O Corazza
- Department of Clinical, Pharmaceutical and Biological Sciences, University of Hertfordshire, UK; Department of Psychology and Cognitive Science, University of Trento, Italy
| | - R Csako
- Department of Psychology and Neuroscience, Auckland University of Technology, Auckland, New Zealand
| | | | - H Fujiwara
- Department of Neuropsychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Decentralized Big Data Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan
| | | | - J Fuss
- Institute of Forensic Psychiatry and Sex Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany
| | - R Gabrhelík
- Charles University, First Faculty of Medicine, Department of Addictology, Prague, Czech Republic; General University Hospital in Prague, Department of Addictology, Czech Republic
| | - B Gjoneska
- Macedonian Academy of Sciences and Arts, Macedonia
| | - M Gola
- Institute of Psychlogy, Polish Academy of Sciences, Poland; Institute for Neural Computations, University of California San Diego, USA
| | - J B Grubbs
- University of New Mexico, Albuquerque, USA; Center for Alcohol, Substance Use, And Addiction (CASAA), University of New Mexico, Albuquerque, USA
| | - H T Hashim
- University of Baghdad, College of Medicine, Iraq
| | - M S Islam
- Department of Public Health and Informatics, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh; Centre for Advanced Research Excellence in Public Health, Savar, Dhaka 1342, Bangladesh
| | - M Ismail
- University of Baghdad, College of Medicine, Iraq
| | - M C Jiménez-Martínez
- Universidad Pedagógca y Tecnológica de Colombia, Colombia; Grupo de Investigación Biomédica y de Patología, Colombia
| | - T Jurin
- Department of Psychology, Humanities and Social Sciences, University of Zagreb, Croatia
| | - O Kalina
- Department of Educational Psychology and Psychology of Health, Pavol Jozef Safarik University in Kosice, Slovakia
| | - V Klein
- School of Psychology, University of Southampton, UK
| | - A Költő
- Health Promotion Research Centre, University of Galway, Ireland, UK
| | - S-K Lee
- Department of Psychiatry, Hallym University Chuncheon Sacred Heart Hospital, South Korea; Chuncheon Addiction Management Center, South Korea
| | - K Lewczuk
- Institute of Psychology, Cardinal Stefan Wyszynski University, Warsaw, Poland
| | - C-Y Lin
- Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - C Lochner
- SAMRC Unit on Risk & Resilience in Mental Disorders, Stellenbosch University, South Africa
| | | | - K Lukavská
- Charles University, First Faculty of Medicine, Department of Addictology, Prague, Czech Republic; Charles University, Faculty of Education, Department of Psychology, Prague, Czech Republic
| | - P Mayta-Tristán
- Facultad de Medicina, Universidad Científica del Sur, Lima, Peru
| | - D J Miller
- College of Healthcare Sciences, James Cook University, Australia
| | - O Orosová
- Pavol Jozef Safarik University in Kosice, Department of Educational Psychology and Psychology of Health, Slovakia
| | | | - F P Ponce
- Facultad de Psicología, Universidad de Talca, Chile
| | - G R Quintana
- Departamento de Psicología y Filosofía, Facultad de Ciencias Sociales, Universidad de Tarapacá, Arica, Arica y Parinacota, Chile
| | - G C Quintero Garzola
- Florida State University, Panama; Sistema Nacional de Investigación (SNI), SENACYT, Panama
| | - J Ramos-Diaz
- Facultad de Ciencias de la Salud, Universidad Privada del Norte, Lima, Perú
| | | | - A Rousseau
- Leuven School for Mass Communication, KU Leuven, Leuven, Belgium
| | - M De Tubino Scanavino
- Department of Psychiatry, Faculdade de Medicina, Universidade de São Paulo, Brazil; Experimental Pathophisiology Post Graduation Program, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | | | - P Sharan
- Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, 110029, India
| | - M Shibata
- Department of Neuropsychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - S Shoib
- Department of Psychology, Shardha University, India; Department of Health Kashmir, India
| | - V Sigre-Leirós
- Institute of Psychology, University of Lausanne, Lausanne, Switzerland; Institute of Legal Psychiatry, Lausanne University Hospitals (CHUV), Lausanne, Switzerland
| | - L Sniewski
- Auckland University of Technology, New Zealand
| | - O Spasovski
- Faculty of Philosophy, Ss. Cyril and Methodius University in Skopje, Macedonia; Faculty of Philosophy, University of Ss. Cyril and Methodius in Trnava, Slovakia
| | - V Steibliene
- Laboratory of Behavioral Medicine, Neuroscience Institute, Lithuanian University of Health Sciences, Lithuania
| | - D J Stein
- SAMRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry & Neuroscience Institute, University of Cape Town, South Africa
| | - C Strong
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - B C Ünsal
- Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
| | - M-P Vaillancourt-Morel
- Département de Psychologie, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - M C Van Hout
- Public Health Institute, Faculty of Health, Liverpool John Moores University, UK
| | - B Bőthe
- Département de Psychologie, Université de Montréal, Montréal, Canada; Département de Psychologie, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| |
Collapse
|
2
|
Largeau B, Bergeron S, Auger F, Salmon Gandonnière C, Jonville-Béra AP, Ehrmann S, Gautier S, Bordet R. Experimental Models of Posterior Reversible Encephalopathy Syndrome: A Review From Pathophysiology to Therapeutic Targets. Stroke 2024; 55:484-493. [PMID: 38126184 DOI: 10.1161/strokeaha.123.044533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiological entity characterized by nonspecific symptomatology (eg, headache, visual disturbances, encephalopathy, and seizures) and classically cortical and subcortical vasogenic edema predominantly affecting the parietooccipital region. PRES etiologies are usually dichotomized into toxic PRES (eg, antineoplastic drugs, illicit drugs) and clinical condition-associated PRES (eg, acute hypertension, dysimmune disorders). Although the pathophysiology of PRES remains elusive, 2 main pathogenic hypotheses have been suggested: cerebral hyperperfusion due to acute hypertension and cerebral hypoperfusion related to endothelial dysfunction. Research into the pathogenesis of PRES has emerged through the development of animal models in the last decade. The motivation for developing a suitable PRES model is 2-fold: to fill in knowledge gaps of the pathophysiological mechanisms involved, and to open new perspectives for clinical assessment of pharmacological targets to improve therapeutic management of PRES. All current models of PRES have a hypertensive background, on which other triggers (acute hypertension, inflammatory, drug toxicity) have been added to address specific facets of PRES (eg, seizures). The initial model consisted in inducing a reduced uterine perfusion pressure that mimics preeclampsia, a leading cause of PRES. More recently, a model of stroke-prone spontaneously hypertensive rats on high-salt diet, originally developed for hypertensive small vessel disease and vascular cognitive impairment, has been studied in PRES. This review aims to discuss, depending on the research objective, the benefits and limitations of current experimental approaches and thus to define the desirable characteristics for studying the pathophysiology of PRES and developing new therapies.
Collapse
Affiliation(s)
- Bérenger Largeau
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France (B.L.)
| | - Sandrine Bergeron
- Université de Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille Neuroscience & Cognition, Unité Mixte de Recherche (UMR) 1172, équipe Troubles Cognitifs Dégénératifs et Vasculaires, Centre Hospitalier Universitaire (CHU) de Lille, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance, France (S.B., S.G., R.B.)
| | - Florent Auger
- Université de Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, CHU Lille, Institut Pasteur de Lille, US 41, Unités Mixtes de Service 2014, Plateformes Lilloises en Biologie et Santé, Lille, France (F.A.)
| | - Charlotte Salmon Gandonnière
- CHRU de Tours, Service de Médecine Intensive Réanimation, réseau CRICS-TRIGGERSEP F-CRIN (Clinical Research in Intensive Care Sepsis Trial Group for Global Evaluation Research in Sepsis, a French Clinical Research Infrastructure Network) Research Network, Tours, France (C.S.G.)
| | - Annie-Pierre Jonville-Béra
- Université de Tours, Université de Nantes, INSERM, Methods in Patients-Centered Outcomes and Health Research (SPHERE), UMR 1246, CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France (A.-P.J.-B.)
| | - Stephan Ehrmann
- Université de Tours, INSERM, Centre d'étude des Pathologies Respiratoires (CEPR), UMR 1100, CHRU de Tours, Service de Médecine Intensive Réanimation, CIC 1415, réseau CRICS-TRIGGERSEP F-CRIN Research Network, Tours, France (S.E.)
| | - Sophie Gautier
- Université de Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille Neuroscience & Cognition, Unité Mixte de Recherche (UMR) 1172, équipe Troubles Cognitifs Dégénératifs et Vasculaires, Centre Hospitalier Universitaire (CHU) de Lille, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance, France (S.B., S.G., R.B.)
| | - Régis Bordet
- Université de Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille Neuroscience & Cognition, Unité Mixte de Recherche (UMR) 1172, équipe Troubles Cognitifs Dégénératifs et Vasculaires, Centre Hospitalier Universitaire (CHU) de Lille, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance, France (S.B., S.G., R.B.)
| |
Collapse
|
3
|
de Canecaude C, Montastruc F, Bergeron S, Sanchez-Pena P, Grandvuillemin A. French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19). Therapie 2023; 78:517-522. [PMID: 36918316 PMCID: PMC9943551 DOI: 10.1016/j.therap.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 02/13/2023] [Indexed: 02/23/2023]
Abstract
INTRODUCTION Casirivimab and imdevimab (Ronapreve®) are two recombinant human monoclonal antibodies (mAbs) that bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, preventing the virus from entering cells. In March 2021, this drug was granted emergency use authorisation (EUA) in France for early treatment of COVID-19 in patients at increased risk of progression to severe COVID-19. In August/September 2021, the indication was expanded to COVID-19 prevention (pre- or post-exposure prophylaxis) and treatment of hospitalised patients requiring non-invasive oxygen therapy. The aim of the study was to better describe the adverse drug reaction (ADR) profile and detect safety signals of this new drug used in COVID-19 treatment. METHODS We described ADR profile with casirivimab/imdevimab reported as suspect/interacting drug to the French pharmacovigilance network and the pharmaceutical company between 17/03/2021 and 30/06/2022. Data presented correspond to the 2 periods of the pharmacovigilance survey: the first carried out by the pharmaceutical company for curative and prophylactic uses and the second by Toulouse university regional pharmacovigilance center (RPVC). RESULTS A total of 384 reports were analysed and 256 were "serious". ADR profile was comparable between the 2 periods and between curative and prophylactic use, corresponding to expected ADRs such as infusion-related reactions and hypersensitivity, inefficiencies or worsened infections and deaths. Two potential pharmacovigilance signals were also studied: acute pulmonary oedemas and sudden deaths. DISCUSSION No pharmacovigilance signal emerged from this 15 months French pharmacovigilance survey. Moreover data from published studies are also reassuring. This pharmacovigilance survey was the first one for the new version of EUA and with a new ADR reporting process i.e. declaration to the RPVC instead of the pharmaceutical company. Casirivimab/imdevimab is no longer used in France today but we continue to monitor this drug for any future evidence of resurgent activity on a new variant of Sars-CoV-2.
Collapse
Affiliation(s)
- Claire de Canecaude
- Service de pharmacologie médicale et clinique, centre régional de pharmacovigilance de pharmacoépidémiologie et d'informations sur le médicament (CRPV), centre hospitalier universitaire - Faculté de médecine, 31000 Toulouse, France.
| | - François Montastruc
- Service de pharmacologie médicale et clinique, centre régional de pharmacovigilance de pharmacoépidémiologie et d'informations sur le médicament (CRPV), centre hospitalier universitaire - Faculté de médecine, 31000 Toulouse, France
| | - Sandrine Bergeron
- Service de pharmacologie, centre régional de pharmacovigilance, centre hospitalier universitaire - Faculté de médecine, 59000 Lille, France
| | - Paola Sanchez-Pena
- Centre régional de pharmacovigilance, service de pharmacologie médicale, centre hospitalier universitaire, 33000 Bordeaux, France
| | - Aurélie Grandvuillemin
- Centre régional de pharmacovigilance, centre hospitalier universitaire, 21000 Dijon, France
| |
Collapse
|
4
|
Lemery R, Cariou C, Darrigade AS, Rochefort-Morel C, Carvalho-Lallement P, Tedbirt B, Polard E, Picard S, Bergeron S, Sanchez-Pena P, Dupuy A, Triquet L, Droitcourt C. Immediate hypersensitivity to dupilumab: A French case series. J Allergy Clin Immunol Pract 2023; 11:2608-2610. [PMID: 37178761 DOI: 10.1016/j.jaip.2023.04.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 03/27/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023]
Affiliation(s)
- Romain Lemery
- Dermatology Department, Rennes University Medical Center, Rennes, France
| | - Claire Cariou
- Dermatology Department, Rennes University Medical Center, Rennes, France; Department of Pulmonology and Allergology, Rennes University Medical Center, Rennes, France
| | | | - Cécile Rochefort-Morel
- Department of Pulmonology and Allergology, Rennes University Medical Center, Rennes, France
| | | | - Billal Tedbirt
- Dermatology Department, Rouen University Medical Center, Rouen, France
| | - Elisabeth Polard
- Regional Pharmacovigilance Center, Rennes University Medical Center, Rennes, France
| | - Sylvie Picard
- Regional Pharmacovigilance Center, Rennes University Medical Center, Rennes, France
| | - Sandrine Bergeron
- Regional Pharmacovigilance Center, Lille University Medical Center, Lille, France
| | - Paola Sanchez-Pena
- Regional Pharmacovigilance Center, Bordeaux University Medical Center, Bordeaux, France
| | - Alain Dupuy
- Dermatology Department, Rennes University Medical Center, Rennes, France; Univ Rennes, INSERM, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
| | - Louise Triquet
- Regional Pharmacovigilance Center, Rennes University Medical Center, Rennes, France
| | - Catherine Droitcourt
- Dermatology Department, Rennes University Medical Center, Rennes, France; Univ Rennes, INSERM, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
| |
Collapse
|
5
|
Béné J, Durieux F, Bergeron S, Potey C, Lebrun-Vignes B, Staumont-Sallé D, Gautier S. About two cases of possible topical steroid withdrawal reaction. Therapie 2023; 78:448-451. [PMID: 36096918 DOI: 10.1016/j.therap.2022.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 08/05/2022] [Accepted: 08/26/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Johana Béné
- Department of Pharmacology, Pharmacovigilance Unit, University Hospital of Lille, University of Lille, 59000 Lille, France.
| | - Flore Durieux
- Department of Pharmacology, Pharmacovigilance Unit, University Hospital of Lille, University of Lille, 59000 Lille, France
| | - Sandrine Bergeron
- Department of Pharmacology, Pharmacovigilance Unit, University Hospital of Lille, University of Lille, 59000 Lille, France
| | - Camille Potey
- Department of Pharmacology, Pharmacovigilance Unit, University Hospital of Lille, University of Lille, 59000 Lille, France
| | - Bénédicte Lebrun-Vignes
- Regional Pharmacovigilance Centre, Sorbonne University Hospital Group, AP-HP, 75000 Paris, France; Université Paris Est Créteil (UPEC), Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379, 94000 Créteil, France
| | - Delphine Staumont-Sallé
- Department of Dermatology, University Hospital of Lille, U1286 Inserm INFINITE, University of Lille, 59000 Lille, France
| | - Sophie Gautier
- Department of Pharmacology, Pharmacovigilance Unit, University Hospital of Lille, University of Lille, 59000 Lille, France
| |
Collapse
|
6
|
Barus R, Bergeron S, Chen Y, Gautier S. Sex differences: From preclinical pharmacology to clinical pharmacology. Therapie 2023; 78:189-194. [PMID: 36302696 DOI: 10.1016/j.therap.2022.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Accepted: 08/29/2022] [Indexed: 11/05/2022]
Abstract
Sex is a crucial variable to take into account in medical research. In this review, we attempted to present its importance at all stages of research and even during drug's post-marketing surveillance. Most preclinical research studies do not take sex into account while many diseases are known to present sexual dimorphism. However, a shift in thinking occurred since the January 2016 implementation of the US Institutes of Health recommendations to take sex into account in research. Nevertheless, in preclinical studies, the lack of sex-based statistical analyses persists. Moreover, in humans, women are often under-represented in some clinical trials, despite well-identified sexual dimorphism. In addition, some pathologies are subject to social representations of diseases considered "male" or "female" which can also lead to a delay in diagnosis and management for both sexes. Finally, many drug classes may be subject to sex differences in efficacy and safety. For example, women present more adverse events than men, mainly because of different pharmacokinetic parameters. Accounting sex as a variable from the preclinical phase is essential to improve the transposition of observed results and move towards personalized medicine.
Collapse
Affiliation(s)
- Romain Barus
- Inserm, Pharmacology Department, CHU de Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Université de Lille, 59000 Lille, France
| | - Sandrine Bergeron
- Inserm, Pharmacology Department, CHU de Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Université de Lille, 59000 Lille, France
| | - Yaohua Chen
- Inserm, Pharmacology Department, CHU de Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Université de Lille, 59000 Lille, France
| | - Sophie Gautier
- Inserm, Pharmacology Department, CHU de Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Université de Lille, 59000 Lille, France.
| |
Collapse
|
7
|
Barus R, Bergeron S, Chen Y, Gautier S. Les différences entre les sexes : de la pharmacologie préclinique à la pharmacologie clinique. Therapie 2022. [DOI: 10.1016/j.therap.2022.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
8
|
Carton L, Auger F, Laloux C, Durieux N, Kyheng M, Potey C, Bergeron S, Rolland B, Deguil J, Bordet R. Effects of acute ethanol and/or diazepam exposure on immediate and delayed hippocampal metabolite levels in rats anesthetized with isoflurane. Fundam Clin Pharmacol 2022; 36:687-698. [DOI: 10.1111/fcp.12764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2021] [Revised: 01/13/2022] [Accepted: 01/31/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Louise Carton
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR‐S1172, Pharmacology Department Lille France
| | - Florent Auger
- Lille In vivo Imaging and Functional Exploration platform Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41‐UMS 2014‐PLBS Lille France
| | - Charlotte Laloux
- Lille In vivo Imaging and Functional Exploration platform Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41‐UMS 2014‐PLBS Lille France
| | - Nicolas Durieux
- Lille In vivo Imaging and Functional Exploration platform Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41‐UMS 2014‐PLBS Lille France
| | - Maéva Kyheng
- ULR 2694‐METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales Univ. Lille, CHU Lille Lille France
- Département de Biostatistiques CHU Lille Lille France
| | - Camille Potey
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR‐S1172, Pharmacology Department Lille France
| | - Sandrine Bergeron
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR‐S1172, Pharmacology Department Lille France
| | - Benjamin Rolland
- Service Universitaire d'Addictologie de Lyon CH Le Vinatier, Hospices Civils de Lyon Bron France
- Inserm U1028, CNRS UMR5292 Université Claude Bernard Lyon 1 Bron France
| | - Julie Deguil
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR‐S1172, Pharmacology Department Lille France
| | - Régis Bordet
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR‐S1172, Pharmacology Department Lille France
| |
Collapse
|
9
|
Bergeron S, Barus R, Leboullenger C, Auger F, Bongiovanni A, Tardivel M, Jonneaux A, Laloux C, Potey C, Bordet R, Chen Y, Gautier S. Beneficial effects of atorvastatin on sex-specific cognitive impairment induced by a cerebral microhaemorrhage in mice. Br J Pharmacol 2021; 178:1705-1721. [PMID: 33502755 DOI: 10.1111/bph.15393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 12/31/2020] [Accepted: 01/13/2021] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND AND PURPOSES Cerebral microhaemorrhages (CMHs) are associated with cognitive decline in humans. In rodents, CMHs induces cognitive impairment in male mice along with sex-specific cortical and hippocampal changes affecting neural, glial and vascular functions. Statins, have been proposed to prevent cognitive decline. We tested here the action of atorvastatin on CMH-induced cognitive impairment in a murine model of CMH. EXPERIMENTAL APPROACH Using a multimodal approach combining behavioural tests, in vivo imaging, biochemistry and molecular biology, the effects of oral administration of atorvastatin on the sex-specific changes induced by a cortical CMH were studied in male and female mice (C57BL/6J) at 6-week post-induction using a collagenase-induced model. KEY RESULTS Atorvastatin caused specific effects according to the sex-specific CMH-induced changes. In males, atorvastatin improved the visuospatial memory, induced a local modulation of microglial response and enhanced brain-derived neurotrophic factor (BDNF)-tropomyosin receptor kinase B (trkB) and vascular endothelial growth factor (VEGF) expression in the cortex. In the hippocampus, atorvastatin increased glucose metabolism and modulated astrocytes morphology. In females, atorvastatin did not modulate visuospatial memory despite the increased expression of cortical BDNF and the decrease in the number of hippocampal astrocytes. Atorvastatin also induced a decrease in the expression of cortical oestrogen receptors but did not modify body weight nor serum cholesterol levels in both sexes. CONCLUSION AND IMPLICATIONS Atorvastatin modulated the sex-specific cognitive impairment induced by the CMH with a pathophysiological impact mainly within the cortical area. It could represent a promising candidate for future sex-stratified clinical trials in patients with CMH.
Collapse
Affiliation(s)
- Sandrine Bergeron
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Pharmacology Department, Degenerative and Vascular Cognitive Disorders, Lille, F-59000, France
| | - Romain Barus
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Pharmacology Department, Degenerative and Vascular Cognitive Disorders, Lille, F-59000, France
| | - Clémence Leboullenger
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, F-59000, France
| | - Florent Auger
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, F-59000, France
| | - Antonino Bongiovanni
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, F-59000, France
| | - Meryem Tardivel
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, F-59000, France
| | - Aurélie Jonneaux
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Pharmacology Department, Degenerative and Vascular Cognitive Disorders, Lille, F-59000, France
| | - Charlotte Laloux
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, F-59000, France
| | - Camille Potey
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Pharmacology Department, Degenerative and Vascular Cognitive Disorders, Lille, F-59000, France
| | - Régis Bordet
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Pharmacology Department, Degenerative and Vascular Cognitive Disorders, Lille, F-59000, France
| | - Yaohua Chen
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Pharmacology Department, Degenerative and Vascular Cognitive Disorders, Lille, F-59000, France
| | - Sophie Gautier
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Pharmacology Department, Degenerative and Vascular Cognitive Disorders, Lille, F-59000, France
| |
Collapse
|
10
|
Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E. [Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis]. Therapie 2020; 76:455-465. [PMID: 33376005 DOI: 10.1016/j.therap.2020.12.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 11/30/2020] [Accepted: 12/03/2020] [Indexed: 10/22/2022]
Abstract
OBJECTIVE The aim of this study was to describe the profile of adverse drug reactions (ADRs) observed with abiraterone and enzalutamide, based on cases registered in the French regional pharmacovigilance centres to identify potential pharmacovigilance signals. METHODS We extracted from the French pharmacovigilance database all cases of ADRs or drug interactions involving abiraterone or enzalutamide from the time they market authorization date until December 31st, 2017. Signal detection results have been transmitted by the French Agency for Health Products (ANSM). The data were compared with those of the risk management plans for each drug and the literature. RESULTS Among the 233 observations analyzed, nearly 62% involved abiraterone as a suspect drug and 38% involved enzalutamide; only 1 case involved both drugs. The ADRs profile is different between the drugs. Abiraterone is mostly associated with expected cardiac diseases (heart failure, and QT prolongation), expected with the drug. Also described, several cases of hepatotoxicity have been reported, however some cases with fatal outcome suggest that despite a follow-up of the liver function tests, it is difficult to anticipate this risk. Signals concerning acute renal failure and ischemic stroke have arisen. Enzalutamide is more particularly associated with various neurological disorders (convulsions, hallucinations, fatigue, and memory impairment) expected with the drug. While ischemic heart disease is also expected, signals of heart failure and atrial fibrillation have arisen. A potential hepatotoxicity of the molecule is discussed because of cases of cholestatic hepatitis. CONCLUSION The analysis of the French pharmacovigilance database cases allows to confirm an expected and monitored risk profile in the risk management plan for both drugs. Several signals have arisen, some of which will be investigated through a pharmacoepidemiology study.
Collapse
Affiliation(s)
- Lucie-Marie Scailteux
- Centre régional de pharmacovigilance, pharmacoépidémiologie et information sur le médicament, CHU de Rennes, rue Henri Le Guilloux, 35000 Rennes, France; EA 7449 REPERES, université Rennes, 35000 Rennes, France.
| | - Clémence Lacroix
- Service de pharmacologie clinique, centre régional de pharmacovigilance, Inserm, institut de neuroscience des systèmes UMR 1106, Aix Marseille université, AP-HM, 13005 Marseille, France
| | - Sandrine Bergeron
- UMR-S1172, degenerative and vascular cognitive disorders, Lille neuroscience and cognition, Inserm, CHU de Lille, université Lille, 59000 Lille, France
| | - Fabien Despas
- Service de pharmacologie médicale et clinique, Inserm 1027, facultés de médecine, CHU, université Paul-Sabatier, 31000 Toulouse, France
| | - Marion Sassier
- Centre régional de pharmacovigilance, pharmacoépidémiologie et information sur le médicament, CHU de Caen, 14000 Caen, France
| | - Louise Triquet
- Centre régional de pharmacovigilance, pharmacoépidémiologie et information sur le médicament, CHU de Rennes, rue Henri Le Guilloux, 35000 Rennes, France
| | - Sylvie Picard
- Centre régional de pharmacovigilance, pharmacoépidémiologie et information sur le médicament, CHU de Rennes, rue Henri Le Guilloux, 35000 Rennes, France
| | - Emmanuel Oger
- Centre régional de pharmacovigilance, pharmacoépidémiologie et information sur le médicament, CHU de Rennes, rue Henri Le Guilloux, 35000 Rennes, France; EA 7449 REPERES, université Rennes, 35000 Rennes, France
| | - Elisabeth Polard
- Centre régional de pharmacovigilance, pharmacoépidémiologie et information sur le médicament, CHU de Rennes, rue Henri Le Guilloux, 35000 Rennes, France; EA 7449 REPERES, université Rennes, 35000 Rennes, France
| | | |
Collapse
|
11
|
Chen YS, Barus R, Bergeron S, Deguil J, Auger F, Durieux N, Skrobala E, Bordet R, Pasquier F, Gautier S. P2-087: EARLY IMPACT INDUCED BY CEREBRAL MICROBLEED IN A MODEL OF TRANSGENIC FEMALE MICE OF ALZHEIMER'S DISEASE. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.2494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Bergeron S, Chen Y, Auger F, Deguil J, Durieux N, Skrobala E, Barus R, Potey C, Cordonnier C, Pasquier F, Ravasi L, Bordet R, Gautier S. Role of cortical microbleeds in cognitive impairment: In vivo behavioral and imaging characterization of a novel murine model. J Cereb Blood Flow Metab 2019; 39:1015-1025. [PMID: 29333917 PMCID: PMC6547192 DOI: 10.1177/0271678x17752765] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cerebral microbleeds (CMBs) could contribute to cognitive impairment in the general population and in patients with dementia. We designed a study to (i) develop a murine model of CMBs, (ii) assess whether CMBs affect cognition in this model and (iii) assess whether this model is sensitive to pharmacological modulation. Male C57Bl6/J mice were stereotactically administered collagenase to induce cortical lesion analysed by MRI at 24 h. CMB-mice were assessed at six weeks post-lesion for cognitive performances (Barnes maze and Touchscreen automated paired-associated learning (PAL) task) and for cerebral metabolism (in vivo PET/CT with fluorodeoxyglucose (FDG)). CMB-model sensitivity to pharmacological modulation was assessed by administering atorvastatin (5 mg/kg/day) over the follow-up period. CMB mice were compared to naïve littermates. Collagenase at 0.8 µU/µl appeared suitable to induce reproducible and reliable CMBs. At six weeks, a decline in learning, spatial and visuospatial memory was significantly observed in CMB-mice. Brain metabolism was impaired in all cortex, striatum and the ipsilateral dentate gyrus. A significant improvement in cognition performances was depicted under atorvastatin. In this novel murine model of CMBs, we validated that CMBs lowered cognitive performances and affected regional metabolism. We also proved that this CMB-model is sensitive to pharmacological modulation.
Collapse
Affiliation(s)
- Sandrine Bergeron
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Yaohua Chen
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Florent Auger
- 2 Univ. Lille, Inserm, CHU Lille, In Vivo Imaging Core Facility, Lille, France
| | - Julie Deguil
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Nicolas Durieux
- 2 Univ. Lille, Inserm, CHU Lille, In Vivo Imaging Core Facility, Lille, France
| | - Emilie Skrobala
- 3 Univ. Lille Labex DISTALZ, CHU Lille, Biostatistics Platform, and memory clinic, Lille, France
| | - Romain Barus
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Camille Potey
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Charlotte Cordonnier
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Florence Pasquier
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Laura Ravasi
- 2 Univ. Lille, Inserm, CHU Lille, In Vivo Imaging Core Facility, Lille, France
| | - Régis Bordet
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Sophie Gautier
- 1 Univ. Lille, Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, Lille, France
| |
Collapse
|
13
|
Bardin M, Brassard A, Dumoulin C, Bergeron S, Mayrand M, Waddell G, Khalifé S, Morin M. 014 Examining the Role of the Physical Therapist in Treatment Response of Provoked Vestibulodynia. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.03.471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Géphine S, Bergeron S, Saey D, Mucci P, Maltais F. Évaluation des capacités fonctionnelles dans la BPCO : le test de lever de chaise d’une minute un exercice maximal ? Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
15
|
Haddad H, Bergeron S, Ignaszewski A, Searles G, Rochdi D, Bastien N. THE PARASAIL STUDY- CANADIAN REAL WORLD EXPERIENCE USE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
16
|
Bastien N, Haddad H, Bergeron S, Ignaszewski A, Searles G. THE PARASAIL STUDY: PATIENT REPORTED OUTCOMES FROM THE CANADIAN REAL WORLD EXPERIENCE USE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
17
|
Ratnani Y, Hébert M, Robichaud M, Duchesne M, Frappier JY, Villemaire-Krajden R, Bergeron S, Lambert Y, Chartrand R, Mcduff P. Health Impact of Adverse Childhood Experiences Among Youths in Custody: The Significant Contribution of Sexual Abuse. Paediatr Child Health 2016. [DOI: 10.1093/pch/21.supp5.e55b] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND: Growing evidence suggests a graded relationship between adverse childhood experiences (ACE) and unfavorable health outcomes as early as in the teenage years. Youths under the welfare protection system represent an especially vulnerable group - presenting traumatic personal trajectory while cumulating family related-risk factors. Among early life adversities, specific experience might have a greatest contribution on the long-term health-risk.
OBJECTIVES: The objective of this analysis is to evaluate the contribution of sexual abuse as compare to other ACEs on different health issues in adolescent under court custody.
DESIGN/METHODS: This is a secondary analysis from a cross-sectional health evaluation study of youths in custodial facilities (2011-13). A total of 315 teenagers 14-17 y.o. (134 girls, 181 boys) completed a self-reported questionnaire about their health status and were then evaluated by a nurse/ doctor using a comprehensive standardized data collection checklist. We identified 8 ACEs: (1) single family; (2) violent death of family member; family history of (3) incarceration, (4) mental health issues, (5) substance abuse; personal history of (6) intrafamilial or (7) extrafamilial physical abuse; personal history of (8) sexual abuse. Multiple and logistic regression were performed between the ACEs and a number of relevant variables.
RESULTS: A personal history of sexual abuse was the most consistant ACE predicting negative health outcomes including perceived health status (R2=0.04; p=0.05), number of health problems identified / acute or chronic (p=0.00), psychosomatic complaints (R2=0.12; p=0.00), sleeping problems (OR=2.8; p=0.005), medication (OR=3.5; p=0.01). This trauma was also the most important factor for high-risk sexuality items evaluated: number of sexuality-related problems in girls (R2=0.15; p=0.00), vaginal sex before 13 y.o. (OR=1.8; p=0.48), number of partners (R2=0.04; p=0.03), sex work (OR=9.6; p=0.00), fear of STI (OR=3.2; p=0.001), as it was for mental health issues: mental health disorders (OR=4.3; p=0.00), suicidal ideation (OR=4.0; p=0.00), suicidal attempt (OR=3.6; p=0.00), self-inflicting injuries (R2=0.12 ; p = 0.01), depression (R2=0.08 ; p=0.00), low self-esteem (R2=0.07; p=0.00) and overdose (OR=2.1; p=0.02).
CONCLUSION: Among ACEs, a personal history of sexual abuse seems to be the most contributing factor for significant health outcomes. Some traumatic or adverse childhood events have a greater burden on subsequent health-risk. A simple question could help identified those at higher risk and higher needs for health services in teens under custody.
Collapse
|
18
|
Carroll M, Morin M, Dumoulin C, Mayrand M, Waddell G, Khalifé S, Bergeron S, Dubois M. 044 E-Recruitment for Clinical Trials in Sexual Medicine – A Rising Method for a Modern World. J Sex Med 2016. [DOI: 10.1016/j.jsxm.2016.04.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Pazmany E, Aerts L, Van Bael J, Bergeron S, Janssen E, Verhaeghe J, Lukas V, Enzlin P. HP-02-003 The Leuven Vulvalgesiometer: improved device to measure genital pain-pressure thresholds in clinical practice and research. J Sex Med 2016. [DOI: 10.1016/j.jsxm.2016.03.108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
20
|
Muthurajan U, Mattiroli F, Bergeron S, Zhou K, Gu Y, Chakravarthy S, Dyer P, Irving T, Luger K. In Vitro Chromatin Assembly: Strategies and Quality Control. Methods Enzymol 2016; 573:3-41. [PMID: 27372747 DOI: 10.1016/bs.mie.2016.01.002] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Chromatin accessibility is modulated by structural transitions that provide timely access to the genetic and epigenetic information during many essential nuclear processes. These transitions are orchestrated by regulatory proteins that coordinate intricate structural modifications and signaling pathways. In vitro reconstituted chromatin samples from defined components are instrumental in defining the mechanistic details of such processes. The bottleneck to appropriate in vitro analysis is the production of high quality, and quality-controlled, chromatin substrates. In this chapter, we describe methods for in vitro chromatin reconstitution and quality control. We highlight the strengths and weaknesses of various approaches and emphasize quality control steps that ensure reconstitution of a bona fide homogenous chromatin preparation. This is essential for optimal reproducibility and reliability of ensuing experiments using chromatin substrates.
Collapse
Affiliation(s)
- U Muthurajan
- University of Colorado at Boulder, Boulder, CO, United States
| | - F Mattiroli
- University of Colorado at Boulder, Boulder, CO, United States
| | - S Bergeron
- University of Colorado at Boulder, Boulder, CO, United States
| | - K Zhou
- University of Colorado at Boulder, Boulder, CO, United States; Colorado State University, Fort Collins, CO, United States
| | - Y Gu
- University of Colorado at Boulder, Boulder, CO, United States; Colorado State University, Fort Collins, CO, United States
| | - S Chakravarthy
- Illinois Institute of Technology, Chicago, IL, United States
| | - P Dyer
- University of Colorado at Boulder, Boulder, CO, United States
| | - T Irving
- Illinois Institute of Technology, Chicago, IL, United States
| | - K Luger
- University of Colorado at Boulder, Boulder, CO, United States; Howard Hughes Medical Institute, University of Colorado at Boulder, Boulder, CO, United States; Institute for Genome Architecture and Function, Colorado State University, Fort Collins, CO, United States.
| |
Collapse
|
21
|
Ratnani Y, Frappier J, Krajden RV, Bergeron S, Lambert Y, Duchesne M, Chartrand R, McDuff P. 196: Do adverse childhood experiences make teenagers more vulnerable? A study about youth in custodial facilities. Paediatr Child Health 2014. [DOI: 10.1093/pch/19.6.e35-191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Le Ven F, Thebault C, Capoulade R, Dahou A, Dumesnil J, Clavel MA, Delarocheliere R, Bergeron S, Rodes Cabau J, Pibarot P. Impact of global LV longitudinal strain on outcomes of high risk patients undergoing transcatheter aortic valve implantation. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p5408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
|
24
|
Pla-Roca M, Leulmi RF, Tourekhanova S, Bergeron S, Laforte V, Moreau E, Gosline SJC, Bertos N, Hallett M, Park M, Juncker D. Antibody colocalization microarray: a scalable technology for multiplex protein analysis in complex samples. Mol Cell Proteomics 2011; 11:M111.011460. [PMID: 22171321 PMCID: PMC3322566 DOI: 10.1074/mcp.m111.011460] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
DNA microarrays were rapidly scaled up from 256 to 6.5 million targets, and although antibody microarrays were proposed earlier, sensitive multiplex sandwich assays have only been scaled up to a few tens of targets. Cross-reactivity, arising because detection antibodies are mixed, is a known weakness of multiplex sandwich assays that is mitigated by lengthy optimization. Here, we introduce (1) vulnerability as a metric for assays. The vulnerability of multiplex sandwich assays to cross-reactivity increases quadratically with the number of targets, and together with experimental results, substantiates that scaling up of multiplex sandwich assays is unfeasible. We propose (2) a novel concept for multiplexing without mixing named antibody colocalization microarray (ACM). In ACMs, both capture and detection antibodies are physically colocalized by spotting to the same two-dimensional coordinate. Following spotting of the capture antibodies, the chip is removed from the arrayer, incubated with the sample, placed back onto the arrayer and then spotted with the detection antibodies. ACMs with up to 50 targets were produced, along with a binding curve for each protein. The ACM was validated by comparing it to ELISA and to a small-scale, conventional multiplex sandwich assay (MSA). Using ACMs, proteins in the serum of breast cancer patients and healthy controls were quantified, and six candidate biomarkers identified. Our results indicate that ACMs are sensitive, robust, and scalable.
Collapse
Affiliation(s)
- M Pla-Roca
- Biomedical Engineering Department, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Gong L, Ye Z, Zeng Z, Xia M, Zhong Y, Yao Y, Lee E, Ionescu A, Dwivedi G, Mahadevan G, Jiminez D, Frenneaux M, Steeds R, Moore C, Samad Z, Jackson K, Castellucci J, Kisslo J, Von Ramm O, D'ascenzi F, Zaca' V, Cameli M, Lisi M, Natali B, Malandrino A, Mondillo S, Barbier P, Guerrini U, Franzosi M, Castiglioni L, Nobili E, Colazzo F, Li Causi T, Sironi L, Tremoli E, Clausen H, Macdonald S, Basaggianis C, Newton J, Cameli M, Lisi M, Bennati E, Reccia R, Malandrino A, Bigio E, Maccherini M, Chiavarelli M, Henein M, Mondillo S, Floria M, Jamart J, Arsenescu Georgescu C, Mantovani F, Barbieri A, Bursi F, Valenti C, Quaglia M, Modena M, Kutty S, Gribben P, Padiyath A, Polak A, Scott C, Waiss M, Danford D, Bech-Hanssen O, Selimovic N, Rundqvist B, Schmiedel L, Hohmann C, Katzke S, Haacke K, Rauwolf T, Strasser R, Tumasyan LR, Adamyan K, Kosmala W, Derzhko R, Przewlocka-Kosmala M, Mysiak A, Stachowska B, Jedrzejuk D, Bednarek-Tupikowska G, Chrzanowski L, Kasprzak J, Wojciechowska C, Wita K, Busz-Papiez B, Gasior Z, Mizia-Stec K, Kukulski T, Gosciniak P, Sinkiewicz W, Moelmen H, Stoylen A, Thorstensen A, Torp H, Dalen H, Groves A, Nicholson G, Lopez L, Goh CW, Ahn H, Byun Y, Kim J, Park J, Lee J, Park J, Kim B, Rhee K, Kim K, Park J, Yoon H, Hong Y, Park H, Kim J, Ahn Y, Jeong M, Cho J, Kang J, Grapsa J, Dawson D, Karfopoulos K, Jakaj G, Punjabi P, Nihoyannopoulos P, Ruisanchez Villar C, Lerena Saenz P, Gonzalez Vilchez F, Gonzalez Fernandez C, Zurbano Goni F, Cifrian Martinez J, Mons Lera R, Ruano Calvo J, Martin Duran R, Vazquez De Prada Tiffe J, Pietrzak R, Werner B, Voillot D, Huttin O, Zinzius P, Schwartz J, Sellal J, Lemoine S, Christophe C, Popovic B, Juilliere Y, Selton-Suty C, Ishii K, Furukawa A, Nagai T, Kataoka K, Seino Y, Shimada K, Yoshikawa J, Tekkesin A, Yildirimturk O, Tayyareci Y, Yurdakul S, Aytekin S, Jaroch J, Loboz-Grudzien K, Bociaga Z, Kowalska A, Kruszynska E, Wilczynska M, Dudek K, Kakihara R, Naruse C, Hironaka H, Tsuzuku T, Cucchini U, Muraru D, Badano L, Solda' E, Tuveri M, Al Nono O, Sarais C, Iliceto S, Santos L, Cortez-Dias N, Ribeiro S, Goncalves S, Jorge C, Carrilho-Ferreira P, Silva D, Silva-Marques J, Lopes M, Diogo A, Hristova K, Vassilev D, Pavlov P, Katova T, Simova I, Kostova V, Esposito R, Santoro A, Schiano Lomoriello V, Raia R, De Palma D, Dores E, De Simone G, Galderisi M, Zaborska B, Makowska E, Pilichowska E, Maciejewski P, Bednarz B, Wasek W, Stec S, Budaj A, Spinelli L, Morisco C, Assante Di Panzillo E, Crispo S, Di Marino S, Trimarco B, Santoro A, Schiano Lomoriello V, Esposito R, Farina F, Innelli P, Rapacciuolo A, Galderisi M, Polgar B, Banyai F, Rokusz L, Tomcsanyi I, Vaszily M, Nieszner E, Borsanyi T, Kerecsen G, Preda I, Kiss RG, Bull S, Suttie J, Augustine D, Francis J, Karamitsos T, Becher H, Prendergast B, Neubauer S, Myerson S, Lodge F, Broyd C, Milton P, Mikhail G, Mayet J, Davies J, Francis D, Clavel MA, Ennezat PV, Marechaux S, Dumesnil J, Bellouin A, Bergeron S, Meimoun P, Le Tourneau T, Pasquet A, Pibarot P, Herrmann S, Stoerk S, Niemann M, Hu K, Voelker W, Ertl G, Weidemann F, Tayyareci Y, Yurdakul S, Yildirimturk O, Aytekin V, Aytekin S, Kogoj P, Ambrozic J, Bunc M, Di Salvo G, Rea A, Castaldi B, Gala S, D'aiello A, Mormile A, Pisacane F, Pacileo G, Russo M, Calabro R, Nguyen L, Ricksten SE, Jeppsson A, Schersten H, Bech-Hanssen O, Boerlage-Van Dijk K, Yong Z, Bouma B, Koch K, Vis M, Piek J, Baan J, Scandura S, Ussia G, Caggegi A, Cammalleri V, Sarkar K, Mangiafico S, Chiaranda' M, Imme' S, Pistritto A, Tamburino C, Ring L, Nair S, Wells F, Shapiro L, Rusk R, Rana B, Madrid Marcano G, Solis Martin J, Gonzalez Mansilla A, Bravo L, Menarguez Palanca C, Munoz P, Bouza E, Yotti R, Bermejo Thomas J, Fernandez Aviles F, Tamayo T, Denes M, Balint O, Csepregi A, Csillik A, Erdei T, Temesvari A, Fernandez-Pastor J, Linde-Estrella A, Cabrera-Bueno F, Pena-Hernandez J, Barrera-Cordero A, Alzueta-Rodriguez F, De Teresa-Galvan E, Merlo M, Pinamonti M, Finocchiaro G, Pyxaras S, Barbati G, Buiatti A, Dilenarda A, Sinagra G, Kuperstein R, Freimark D, Hirsch S, Feinberg M, Arad M, Mitroi C, Garcia Lunar I, Monivas Palomero V, Mingo Santos S, Beltran Correas P, Gonzalez Lopez E, Garcia Pavia P, Gonzalez Mirelis J, Cavero Gibanel M, Alonso Pulpon L, Finocchiaro G, Pinamonti B, Merlo M, Barbati G, Dilenarda A, Sinagra G, Zaidi A, Ghani S, Sheikh N, Gati S, Howes R, Sharma R, Sharma S, Calcagnino M, O'mahony C, Coats C, Cardona M, Garcia A, Murphy E, Lachmann R, Mehta A, Hughes D, Elliott P, Di Bella G, Madaffari A, Donato R, Mazzeo A, Casale M, Zito C, Vita G, Carerj S, Marek D, Indrakova J, Rusinakova Z, Skala T, Kocianova E, Taborsky M, Musca F, De Chiara B, Belli O, Cataldo S, Brunati C, Colussi G, Quattrocchi G, Santambrogio G, Spano F, Moreo A, Rustad L, Nytroen K, Gullestad L, Amundsen B, Aakhus S, Maroz-Vadalazhskaya N, Shumavetc V, Kurganovich S, Seljun Y, Ostrovskiy A, Ostrovskiy Y, Rustad L, Nytroen K, Segers P, Amundsen B, Aakhus S, Przewlocka-Kosmala M, Orda A, Karolko B, Mysiak A, Driessen MMP, Eising JB, Uiterwaal C, Van Der Ent CK, Meijboom FJ, Shang Q, Tam L, Sun J, Sanderson J, Zhang Q, Li E, Yu C, Arroyo Ucar E, De La Rosa Hernandez A, Hernandez Garcia C, Jorge Perez P, Lacalzada Almeida J, Jimenez Rivera J, Duque Garcia A, Barragan Acea A, Laynez Cerdena I, Kaldararova M, Simkova I, Pacak J, Tittel P, Masura J, Tadic M, Ivanovic B, Zlatanovic M, Damjanov N, Maggiolini S, Gentile G, Bozzano A, Suraci S, Meles E, Carbone C, Tempesta A, Malafronte C, Piatti L, Achilli F, Luijendijk P, Stevens A, De Bruin-Bon H, Vriend J, Van Den Brink R, Vliegen H, Mulder B, Bouma B, Chow V, Ng A, Chung T, Kritharides L, Iancu M, Serban M, Craciunescu I, Hodo A, Ghiorghiu I, Popescu B, Ginghina C, Styczynski G, Szmigielski CA, Kaczynska A, Leszczynski J, Rosinski G, Kuch-Wocial A, Slavich M, Ancona M, Fisicaro A, Oppizzi M, Marone E, Bertoglio L, Melissano G, Margonato A, Chiesa R, Agricola E, Zito C, Mohammed M, Cusma-Piccione M, Piluso S, Arcidiaco S, Nava R, Giuffre R, Ciraci L, Ferro M, Carerj S, Uusitalo V, Luotolahti M, Pietila M, Wendelin-Saarenhovi M, Hartiala J, Saraste M, Knuuti J, Saraste A, Kochanowski J, Scislo P, Piatkowski R, Grabowski M, Marchel M, Roik M, Kosior D, Opolski G, Bartko PE, Graf S, Khorsand A, Rosenhek R, Burwash I, Beanlands R, Clavel MA, Baumgartner H, Pibarot P, Mundigler G, Kudrnova S, Apor A, Huttl H, Kudrnova S, Apor A, Huttl H, Mori F, Santoro G, Oddo A, Rosso G, Meucci F, Pieri F, Squillantini G, Gensini G, Scislo P, Kochanowski J, Piatkowski R, Roik M, Postula M, Opolski G, Park DG, Hong JY, Kim SE, Lee JH, Han KR, Oh DJ, Muraru D, Dal Bianco L, Beraldo M, Solda' E, Cucchini U, Peluso D, Tuveri M, Al Mamary A, Badano L, Iliceto S, Aggeli C, Felekos I, Poulidakis E, Pietri P, Roussakis G, Siasos G, Stefanadis C, Furukawa A, Hoshiba H, Miyasaka C, Sato H, Nagai T, Yamanaka A, Kataoka K, Seino Y, Ishii K, Lilli A, Baratto M, Magnacca M, Comella A, Poddighe R, Talini E, Canale M, Chioccioli M, Del Meglio J, Casolo G, Kuznetsov VA, Melnikov NN, Krinochkin DV, Calin A, Enache R, Popescu B, Beladan C, Rosca M, Lupascu L, Purcarea F, Calin C, Gurzun M, Ginghina C, Dulgheru R, Ciobanu A, Magda S, Mihaila S, Rimbas R, Margulescu A, Cinteza M, Vinereanu D, Sumin AN, Arhipov O, Yoon J, Moon J, Rim S, Nyktari E, Patrianakos A, Solidakis G, Psathakis E, Parthenakis F, Vardas P, Kordybach M, Kowalski M, Kowalik E, Hoffman P, Nagy KV, Kutyifa V, Edes E, Apor A, Merkely B, Gerlach A, Rost C, Schmid M, Rost M, Flachskampf F, Daniel W, Breithardt O, Altekin E, Karakas S, Yanikoglu A, Er A, Baktir A, Demir I, Deger N, Klitsie L, Hazekamp M, Roest A, Van Der Hulst A, Gesink- Van Der Veer B, Kuipers I, Blom N, Ten Harkel A, Farsalinos K, Tsiapras D, Kyrzopoulos S, Avramidou E, Vasilopoulou D, Voudris V, Werner B, Florianczyk T, Ivanovic B, Tadic M, Kalinowski M, Szulik M, Streb W, Rybus-Kalinowska B, Sliwinska A, Stabryla J, Kukla M, Nowak J, Kukulski T, Kalarus Z, Florescu M, Mihalcea D, Magda L, Suran B, Enescu O, Mincu R, Cinteza M, Vinereanu D, Salerno G, Scognamiglio G, D'andrea A, Dinardo G, Gravino R, Sarubbi B, Disalvo G, Pacileo G, Russo M, Calabro R, Liao JN, Sung S, Chen C, Park S, Shin S, Kim M, Shim S, Yildirimturk O, Helvacioglu F, Ulusoy O, Duran C, Tayyareci Y, Yurdakul S, Aytekin S, Kirschner R, Simor T, Moreo A, Ambrosio G, De Chiara B, Tran T, Raman S, Vidal Perez RC, Carreras F, Leta R, Pujadas S, Barros A, Hidalgo A, Alomar X, Pons-Llado G, Olofsson M, Boman K, Ledakowicz-Polak A, Polak L, Zielinska M, Fontana A, Schirone V, Mauro A, Zambon A, Giannattasio C, Trocino G, Dekleva M, Dungen H, Inkrot S, Gelbrich G, Suzic Lazic J, Kleut M, Markovic Nikolic N, Waagstein F, Khoor S, Balogh N, Simon I, Fugedi K, Kovacs I, Khoor M, Florian G, Kocsis A, Szuszai T, O'driscoll J, Saha A, Smith R, Gupta S, Sharma R, Lenkey Z, Gaszner B, Illyes M, Sarszegi Z, Horvath IG, Magyari B, Molnar F, Cziraki A, Elnoamany MF, Badran H, Ebraheem H, Reda A, Elsheekh N. Poster Session 5: Saturday 10 December 2011, 08:30-12:30 * Location: Poster Area. European Journal of Echocardiography 2011. [DOI: 10.1093/ejechocard/jer218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
26
|
Clavel M, Rodés-Cabau J, Bergeron S, Dumont É, Bagur R, De Larochelière R, Doyle D, Lemieux J, Dumesnil J, Pibarot P. 463 Methods and determinants of doppler-echocardiographic measures of prosthetic valve effective area following transcatheter aortic implantation. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
27
|
Clavel M, Ennezat P, Maréchaux S, Dumesnil J, Hachicha Z, Mathieu P, Bellouin A, Bergeron S, Meimoun P, Arsenault M, Tourneau TL, Pasquet A, Couture C, Trahan S, Sackett M, Pibarot P. 520 Utility of stress echocardiography to confirm stenosis severity and predict outcome in patients with low flow, low gradient aortic stenosis and preserved lv ejection fraction. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.437] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
28
|
Clavel MA, Webb JG, Rodés-Cabau J, Masson JB, Dumont E, De Larochellière R, Doyle D, Bergeron S, Baumgartner H, Burwash IG, Dumesnil JG, Mundigler G, Moss R, Kempny A, Bagur R, Bergler-Klein J, Gurvitch R, Mathieu P, Pibarot P. Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation 2010; 122:1928-36. [PMID: 20975002 DOI: 10.1161/circulationaha.109.929893] [Citation(s) in RCA: 210] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Patients with severe aortic stenosis and reduced left ventricular ejection fraction (LVEF) have a poor prognosis with conservative therapy but a high operative mortality when treated surgically. Recently, transcatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement (SAVR) for patients considered at high or prohibitive operative risk. The objective of this study was to compare TAVI and SAVR with respect to postoperative recovery of LVEF in patients with severe aortic stenosis and reduced LV systolic function. METHODS AND RESULTS Echocardiographic data were prospectively collected before and after the procedure in 200 patients undergoing SAVR and 83 patients undergoing TAVI for severe aortic stenosis (aortic valve area ≤1 cm(2)) with reduced LV systolic function (LVEF ≤50%). TAVI patients were significantly older (81±8 versus 70±10 years; P<0.0001) and had more comorbidities compared with SAVR patients. Despite similar baseline LVEF (34±11% versus 34±10%), TAVI patients had better recovery of LVEF compared with SAVR patients (ΔLVEF, 14±15% versus 7±11%; P=0.005). At the 1-year follow-up, 58% of TAVI patients had a normalization of LVEF (>50%) as opposed to 20% in the SAVR group. On multivariable analysis, female gender (P=0.004), lower LVEF at baseline (P=0.005), absence of atrial fibrillation (P=0.01), TAVI (P=0.007), and larger increase in aortic valve area after the procedure (P=0.01) were independently associated with better recovery of LVEF. CONCLUSION In patients with severe aortic stenosis and depressed LV systolic function, TAVI is associated with better LVEF recovery compared with SAVR. TAVI may provide an interesting alternative to SAVR in patients with depressed LV systolic function considered at high surgical risk.
Collapse
Affiliation(s)
- M A Clavel
- Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Laval University, Québec, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
A 74-year-old man presented for shortness of breath. Echocardiography revealed the presence of a large pericardial effusion with signs of tamponade. A right atrial mass was suspected and later confirmed by transesophageal echocardiography. The mass was attached to the right side of the interatrial septum. Surgical resection was performed. Histology was compatible with a diagnosis of undifferentiated B-cell non-Hodgkin's (Burkittlike) primary cardiac lymphoma. The present report provides the first description of a Burkitt-like primary cardiac lymphoma. The presence of a mass in the right atria should raise the possibility of a malignant cardiac tumour. Transesophageal echocardiography should be considered as the initial diagnostic procedure to be performed. Rapid histological diagnosis is important because systemic therapy can influence prognosis in the presence of a primary cardiac lymphoma.
Collapse
Affiliation(s)
- S Legault
- Department of Cardiology, Quebec Heart Institute, Laval Hospital, Quebec City, Canada
| | | | | | | | | | | |
Collapse
|
30
|
Morin M, Bergeron S. La rééducation périnéale dans le traitement de la dyspareunie chez la femme. Sexologies 2009. [DOI: 10.1016/j.sexol.2009.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
|
32
|
Bailey B, Bergeron S, Gravel J, Daoust R. Comparison of Four Pain Scales in Children with Acute Abdominal Pain in a Pediatric Emergency Department. Acad Emerg Med 2007. [DOI: 10.1197/j.aem.2007.03.952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
33
|
Bailey B, Bergeron S, Gravel J, Bussieres JF, Bensoussan A. Efficacy and Impact of Intravenous Morphine before Surgical Consult in Children with Right Lower Quadrant Pain Suggestive of Appendicitis: A Randomized Controlled Trial. Acad Emerg Med 2007. [DOI: 10.1197/j.aem.2007.03.951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
34
|
Gravel J, Gouin S, Bailey B, Roy M, Bergeron S, Amre D. Evaluation of the Validity of a Computerized Version of the Canadian Triage and Acuity Scale in a Pediatric Emergency Department. Acad Emerg Med 2007. [DOI: 10.1197/j.aem.2007.03.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
35
|
Roy M, Carrière B, Thivierge R, Bergeron S. Programme d'enseignement de la pédiatrie aux urgences. Arch Pediatr 2005; 12:712-4. [PMID: 15904780 DOI: 10.1016/j.arcped.2005.04.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M Roy
- Urgence pédiatrique, département de pédiatrie, hôpital Sainte-Justine, université de Montréal, Montréal, Québec, Canada
| | | | | | | |
Collapse
|
36
|
Ploin D, Rousson A, Vitoux-Brot C, Nouyrigat V, Foucaud P, Lemaire JP, Chevallier B, Bergeron S, Martinot A, Chéron G, Floret D. [Treatment of exacerbation of asthma: what are today's issues?]. Arch Pediatr 2005; 12:351-6. [PMID: 15734138 DOI: 10.1016/j.arcped.2004.11.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
During past decades, major progress has been accomplished in the management of acute asthma. Most recent recommendations include evidence-based rationale. The improved quality of clinical guidelines makes them efficient models for medical education. The pediatric pharmacopoeia provides a great variety of choices of drugs as well as for asthma medical devices. These innovations dramatically facilitated the medical management of asthmatic children, but they did not solve all problems. Physicians now use higher doses of salbutamol, but the early prescription of systemic glucocorticoids for moderate exacerbation of asthma is still underused, given the most recent clinical guidelines and meta-analysis. Furthermore, repeated emergency department visits to the wards and lack of primary care physician should systematically be appraised when evaluating severity, as they are both major risk factors for severe exacerbations, even though they are not considered in acute asthma severity scores. Finally, initiating (or reinforcing) patient education at the time of exacerbation also presents important challenges, as emergency visits are a favorable moment to commence the therapeutic education of the child and his family. Indeed, framing the controller medications and educating families about how to manage the disease and to improve their domestic environment are the genuine tools available for the prevention of asthma exacerbations, and particularly those most severe.
Collapse
Affiliation(s)
- D Ploin
- DIM des hospices civils de Lyon, 162, avenue Lacassagne, 69424 Lyon cedex 03 et Réseau d'Epidémiologie Clinique International Francophone (RECIF), Université Claude-Bernard-Lyon I, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Bergeron S, Delage C, Dujardin T, Latulippe É. L’expérience des néphrectomies partielles à l’Hôtel-Dieu de Québec : étude clinico-pathologique de 79 cas consécutifs. Ann Pathol 2005. [DOI: 10.1016/s0242-6498(05)86192-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Gouin S, Trieu TV, Patel H, Bergeron S, Amre D, Guérin R. 124 The Effect of Picture Archiving and Communications Systems on the Diagnostic Performance of Pediatric Emergency Physicians. Paediatr Child Health 2004. [DOI: 10.1093/pch/9.suppl_a.57ab] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Bergeron S, Harvey I, Tanguay C, Morin C, Deschênes J, Bernier V, Meisels A. L’évolution des atypies des cellules glandulaires de signification indéterminée (AGUS) au CHA-Pavillon St-Sacrement. Ann Pathol 2004. [DOI: 10.1016/s0242-6498(04)93929-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Gouin S, Trieu TV, Bergeron S, Patel H, Guérin R. Interpretation of Plain Radiographs by Pediatric Emergency Physicians: Do We Need Routine Review by a Radiologist? Paediatr Child Health 2003. [DOI: 10.1093/pch/8.suppl_b.42ba] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Sterescu A, Gauthier M, Chevalier I, Bergeron S, Brunet S, Taddeo D. Treatment of Febrile Urinary Tract Infections (Uti) in Young Children With Intravenous Antibiotics in a Day Treatment Center. Paediatr Child Health 2003. [DOI: 10.1093/pch/8.suppl_b.43b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Bergeron S, Leduc N, Champagne F, Ste-Marie G, Lafrance M. Factors Influencing Parental Decision in Seeking Emergency Services for Non Urgent Visits. Paediatr Child Health 2003. [DOI: 10.1093/pch/8.suppl_b.41bb] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
|
44
|
Bergeron S, Lebel MH. Pediatric Bacteremia in Emergency Department (ED): Era Before Conjugated Pneumococcal Vaccine. Paediatr Child Health 2002. [DOI: 10.1093/pch/7.suppl_a.42ab] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Gravel J, Bergeron S, Amre D, Gouin S. Evaluation of the Canadian Pediatric Triage and Acuity Scale in an Emergency Department. Paediatr Child Health 2002. [DOI: 10.1093/pch/7.suppl_a.19aa] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Gravel J, Gouin S, Bergeron S, Amre D, Lacroix J. Evaluation of the Pediatric Risk of Admission (PRISA) Score in a Pediatric Emergency Department. Paediatr Child Health 2002. [DOI: 10.1093/pch/7.suppl_a.60a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Bergeron S, Gouin S, Bailey B, Amre D, Patel H. Agreement Among Pediatric Health Care Professionals with New Triage Guidelines. Paediatr Child Health 2002. [DOI: 10.1093/pch/7.suppl_a.26ab] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Bergeron S. Agreement among Pediatric Health Care Professionals with New Triage Guidelines. Acad Emerg Med 2002. [DOI: 10.1197/aemj.9.5.525-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
49
|
Affiliation(s)
- S Bergeron
- Department of Sexology, Université du Québec à Montréal, Department of Psychology, McGill University Health Centre, Royal Victoria Hospital
| | | | | |
Collapse
|
50
|
Bergeron S, Demers C, Bogaty P, Poirier P. The endocarditis that was not: an unusual case of heparin-induced thrombocytopenia with unusual complications. Can J Cardiol 2001; 17:1180-2. [PMID: 11726986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023] Open
Abstract
The complications of heparin-induced thrombocytopenia have been well described previously. However, evidence of the possibility that heparin-induced thrombocytopenia can trigger a thyroid storm has never been published before. A catastrophic evolution of a man referred with a high endocarditis suspicion previously treated with heparin, who successively developed arterial thrombosis and thyroid storm, is described.
Collapse
Affiliation(s)
- S Bergeron
- Québec Heart Institute at Laval Hospital, Sainte-Foy, Canada
| | | | | | | |
Collapse
|